APO Research
Talk to an analyst

APO RESEARCH · REPORT

Orphan Drug Development

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Orphan Drug Development Market Outlook and Growth Opportunities 2026

2 May 2026196 pages

Choose your research edition.

Industry ResearchOrphan Drug Development Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Orphan Drug Development Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Orphan Drug Development Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orphan Drug Development Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Orphan Drug Development Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Orphan Drug Development market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Orphan Drug Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Orphan Drug Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Orphan Drug Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Orphan Drug Development market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Orphan Drug Development market include Novartis, Roche, Celgene, BMS, Shire, Merck, J&J, Pfizer and Biogen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Orphan Drug Development market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Orphan Drug Development and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Orphan Drug Development revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Orphan Drug Development market.

Orphan Drug Development Segment by Company

Novartis

Roche

Celgene

BMS

Shire

Merck

J&J

Pfizer

Biogen

Sanofi

AstraZeneca

Takeda

Orphan Drug Development Segment by Type

Pediatric Orphan Drugs

Adult Orphan Drugs

Orphan Drug Development Segment by Application

Congenital and Genetic Diseases

Tumors and Cancer

Endocrine Diseases

Others

Orphan Drug Development Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Orphan Drug Development status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Orphan Drug Development key companies, revenue, market share, and recent developments.

3. To split the Orphan Drug Development breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Orphan Drug Development market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Orphan Drug Development significant trends, drivers, influence factors in global and regions.

6. To analyze Orphan Drug Development competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orphan Drug Development market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orphan Drug Development and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orphan Drug Development.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Orphan Drug Development industry.

Chapter 3: Detailed analysis of Orphan Drug Development company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Orphan Drug Development in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Orphan Drug Development in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Orphan Drug Development Industry Trends Table 2. Orphan Drug Development Industry Drivers Table 3. Orphan Drug Development Industry Opportunities and Challenges Table 4. Orphan Drug Development Industry Restraints Table 5. Global Orphan Drug Development Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Orphan Drug Development Revenue Share by Company (2021-2026) Table 7. Global Orphan Drug Development Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Orphan Drug Development Key Company Manufacturing Base & Headquarters Table 9. Global Orphan Drug Development Company, Product Type & Application Table 10. Global Orphan Drug Development Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Orphan Drug Development by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Pediatric Orphan Drugs Table 15. Significant Companies of Adult Orphan Drugs Table 16. Global Orphan Drug Development Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Orphan Drug Development Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Orphan Drug Development Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Orphan Drug Development Sales Value Share by Type (2021-2026) Table 20. Global Orphan Drug Development Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Congenital and Genetic Diseases Table 22. Significant Companies of Tumors and Cancer Table 23. Significant Companies of Endocrine Diseases Table 24. Significant Companies of Others Table 25. Global Orphan Drug Development Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Orphan Drug Development Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Orphan Drug Development Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Orphan Drug Development Sales Value Share by Application (2021-2026) Table 29. Global Orphan Drug Development Sales Value Share by Application (2027-2032) Table 30. Global Orphan Drug Development Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Orphan Drug Development Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Orphan Drug Development Sales Value Share by Region (2021-2026) Table 33. Global Orphan Drug Development Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Orphan Drug Development Sales Value Share by Region (2027-2032) Table 35. Global Orphan Drug Development Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Orphan Drug Development Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Orphan Drug Development Sales Value Market Share by Country (2021-2026) Table 38. Global Orphan Drug Development Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Orphan Drug Development Sales Value Market Share by Country (2027-2032) Table 40. Novartis Company Information Table 41. Novartis Business Overview Table 42. Novartis Orphan Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Novartis Orphan Drug Development Product Portfolio Table 44. Novartis Recent Development Table 45. Roche Company Information Table 46. Roche Business Overview Table 47. Roche Orphan Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Roche Orphan Drug Development Product Portfolio Table 49. Roche Recent Development Table 50. Celgene Company Information Table 51. Celgene Business Overview Table 52. Celgene Orphan Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Celgene Orphan Drug Development Product Portfolio Table 54. Celgene Recent Development Table 55. BMS Company Information Table 56. BMS Business Overview Table 57. BMS Orphan Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. BMS Orphan Drug Development Product Portfolio Table 59. BMS Recent Development Table 60. Shire Company Information Table 61. Shire Business Overview Table 62. Shire Orphan Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Shire Orphan Drug Development Product Portfolio Table 64. Shire Recent Development Table 65. Merck Company Information Table 66. Merck Business Overview Table 67. Merck Orphan Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Merck Orphan Drug Development Product Portfolio Table 69. Merck Recent Development Table 70. J&J Company Information Table 71. J&J Business Overview Table 72. J&J Orphan Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. J&J Orphan Drug Development Product Portfolio Table 74. J&J Recent Development Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer Orphan Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Pfizer Orphan Drug Development Product Portfolio Table 79. Pfizer Recent Development Table 80. Biogen Company Information Table 81. Biogen Business Overview Table 82. Biogen Orphan Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Biogen Orphan Drug Development Product Portfolio Table 84. Biogen Recent Development Table 85. Sanofi Company Information Table 86. Sanofi Business Overview Table 87. Sanofi Orphan Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Sanofi Orphan Drug Development Product Portfolio Table 89. Sanofi Recent Development Table 90. AstraZeneca Company Information Table 91. AstraZeneca Business Overview Table 92. AstraZeneca Orphan Drug Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. AstraZeneca Orphan Drug Development Product Portfolio Table 94. AstraZeneca Recent Development Table 95. Takeda Company Information Table 96. Takeda Business Overview Table 97. Takeda Orphan Drug Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Takeda Orphan Drug Development Product Portfolio Table 99. Takeda Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Orphan Drug Development Product Image Figure 2. Global Orphan Drug Development Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Orphan Drug Development Market Size (2021-2032) & (US$ Million) Figure 4. Global Orphan Drug Development Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Pediatric Orphan Drugs Image Figure 8. Adult Orphan Drugs Image Figure 9. Global Orphan Drug Development Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Orphan Drug Development Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Orphan Drug Development Sales Value Share by Type (2021-2032) Figure 12. Congenital and Genetic Diseases Image Figure 13. Tumors and Cancer Image Figure 14. Endocrine Diseases Image Figure 15. Others Image Figure 16. Global Orphan Drug Development Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Orphan Drug Development Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Orphan Drug Development Sales Value Share by Application (2021-2032) Figure 19. Global Orphan Drug Development Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Orphan Drug Development Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Orphan Drug Development Sales Value (2021-2032) & (US$ Million) Figure 22. North America Orphan Drug Development Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Orphan Drug Development Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Orphan Drug Development Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Orphan Drug Development Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Orphan Drug Development Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Orphan Drug Development Sales Value (2021-2032) & (US$ Million) Figure 28. South America Orphan Drug Development Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Orphan Drug Development Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Orphan Drug Development Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Orphan Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Orphan Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Orphan Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Pediatric Orphan Drugs
  • Adult Orphan Drugs
Applications
  • Congenital and Genetic Diseases
  • Tumors and Cancer
  • Endocrine Diseases
  • Others
Companies covered
  • Novartis
  • Roche
  • Celgene
  • BMS
  • Shire
  • Merck
  • J&J
  • Pfizer
  • Biogen
  • Sanofi
  • AstraZeneca
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Orphan Drug Development Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Orphan Drug Development Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Orphan Drug Development Market Dynamics
  1. 2.1 Orphan Drug Development Industry Trends
  2. 2.2 Orphan Drug Development Industry Drivers
  3. 2.3 Orphan Drug Development Industry Opportunities and Challenges
  4. 2.4 Orphan Drug Development Industry Restraints
3 Orphan Drug Development Market by Company
  1. 3.1 Global Orphan Drug Development Company Revenue Ranking in 2025
  2. 3.2 Global Orphan Drug Development Revenue by Company (2021-2026)
  3. 3.3 Global Orphan Drug Development Company Ranking (2024-2026)
  4. 3.4 Global Orphan Drug Development Company Manufacturing Base and Headquarters
  5. 3.5 Global Orphan Drug Development Company Product Type and Application
  6. 3.6 Global Orphan Drug Development Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Orphan Drug Development Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Orphan Drug Development Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Orphan Drug Development Market by Type
  1. 4.1 Orphan Drug Development Type Introduction
  2. 4.1.1 Pediatric Orphan Drugs
  3. 4.1.2 Adult Orphan Drugs
  4. 4.2 Global Orphan Drug Development Sales Value by Type
  5. 4.2.1 Global Orphan Drug Development Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Orphan Drug Development Sales Value by Type (2021-2032)
  7. 4.2.3 Global Orphan Drug Development Sales Value Share by Type (2021-2032)
5 Orphan Drug Development Market by Application
  1. 5.1 Orphan Drug Development Application Introduction
  2. 5.1.1 Congenital and Genetic Diseases
  3. 5.1.2 Tumors and Cancer
  4. 5.1.3 Endocrine Diseases
  5. 5.1.4 Others
  6. 5.2 Global Orphan Drug Development Sales Value by Application
  7. 5.2.1 Global Orphan Drug Development Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Orphan Drug Development Sales Value by Application (2021-2032)
  9. 5.2.3 Global Orphan Drug Development Sales Value Share by Application (2021-2032)
6 Orphan Drug Development Regional Value Analysis
  1. 6.1 Global Orphan Drug Development Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Orphan Drug Development Sales Value by Region (2021-2032)
  3. 6.2.1 Global Orphan Drug Development Sales Value by Region: 2021-2026
  4. 6.2.2 Global Orphan Drug Development Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Orphan Drug Development Sales Value (2021-2032)
  7. 6.3.2 North America Orphan Drug Development Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Orphan Drug Development Sales Value (2021-2032)
  10. 6.4.2 Europe Orphan Drug Development Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Orphan Drug Development Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Orphan Drug Development Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Orphan Drug Development Sales Value (2021-2032)
  16. 6.6.2 South America Orphan Drug Development Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Orphan Drug Development Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Orphan Drug Development Sales Value Share by Country, 2025 VS 2032
7 Orphan Drug Development Country-level Value Analysis
  1. 7.1 Global Orphan Drug Development Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Orphan Drug Development Sales Value by Country (2021-2032)
  3. 7.2.1 Global Orphan Drug Development Sales Value by Country (2021-2026)
  4. 7.2.2 Global Orphan Drug Development Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Orphan Drug Development Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Orphan Drug Development Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Orphan Drug Development Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Orphan Drug Development Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Orphan Drug Development Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Orphan Drug Development Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Orphan Drug Development Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Orphan Drug Development Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Orphan Drug Development Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Orphan Drug Development Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Orphan Drug Development Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Orphan Drug Development Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Orphan Drug Development Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Orphan Drug Development Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Orphan Drug Development Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Orphan Drug Development Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Orphan Drug Development Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Orphan Drug Development Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Orphan Drug Development Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Orphan Drug Development Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Orphan Drug Development Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Orphan Drug Development Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Orphan Drug Development Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Orphan Drug Development Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Orphan Drug Development Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Orphan Drug Development Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Orphan Drug Development Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Orphan Drug Development Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Orphan Drug Development Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Orphan Drug Development Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Orphan Drug Development Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Orphan Drug Development Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Orphan Drug Development Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche Orphan Drug Development Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Celgene
  14. 8.3.1 Celgene Company Information
  15. 8.3.2 Celgene Business Overview
  16. 8.3.3 Celgene Orphan Drug Development Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Celgene Orphan Drug Development Product Portfolio
  18. 8.3.5 Celgene Recent Developments
  19. 8.4 BMS
  20. 8.4.1 BMS Company Information
  21. 8.4.2 BMS Business Overview
  22. 8.4.3 BMS Orphan Drug Development Revenue and Gross Margin (2021-2026)
  23. 8.4.4 BMS Orphan Drug Development Product Portfolio
  24. 8.4.5 BMS Recent Developments
  25. 8.5 Shire
  26. 8.5.1 Shire Company Information
  27. 8.5.2 Shire Business Overview
  28. 8.5.3 Shire Orphan Drug Development Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shire Orphan Drug Development Product Portfolio
  30. 8.5.5 Shire Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Orphan Drug Development Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Orphan Drug Development Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 J&J
  38. 8.7.1 J&J Company Information
  39. 8.7.2 J&J Business Overview
  40. 8.7.3 J&J Orphan Drug Development Revenue and Gross Margin (2021-2026)
  41. 8.7.4 J&J Orphan Drug Development Product Portfolio
  42. 8.7.5 J&J Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Orphan Drug Development Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Orphan Drug Development Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Biogen
  50. 8.9.1 Biogen Company Information
  51. 8.9.2 Biogen Business Overview
  52. 8.9.3 Biogen Orphan Drug Development Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Biogen Orphan Drug Development Product Portfolio
  54. 8.9.5 Biogen Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Orphan Drug Development Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Orphan Drug Development Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Orphan Drug Development Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Orphan Drug Development Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 Takeda
  68. 8.12.1 Takeda Company Information
  69. 8.12.2 Takeda Business Overview
  70. 8.12.3 Takeda Orphan Drug Development Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Takeda Orphan Drug Development Product Portfolio
  72. 8.12.5 Takeda Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst